 Gary Chmielewski
Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 20 | 2020 | 753 | 1.870 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 11 | 2017 | 367 | 1.110 |
Why?
| | Thoracotomy | 4 | 2016 | 34 | 0.930 |
Why?
| | Pneumonectomy | 5 | 2020 | 89 | 0.830 |
Why?
| | Esophageal Neoplasms | 3 | 2015 | 61 | 0.720 |
Why?
| | Thoracic Surgery, Video-Assisted | 3 | 2020 | 22 | 0.680 |
Why?
| | Unnecessary Procedures | 2 | 2019 | 30 | 0.630 |
Why?
| | Adenocarcinoma | 7 | 2015 | 235 | 0.630 |
Why?
| | Esophagectomy | 2 | 2011 | 25 | 0.570 |
Why?
| | Barrett Esophagus | 4 | 2015 | 19 | 0.570 |
Why?
| | Catheter Ablation | 4 | 2015 | 78 | 0.530 |
Why?
| | Esophageal Diseases | 1 | 2011 | 7 | 0.460 |
Why?
| | Jejunostomy | 1 | 2011 | 8 | 0.460 |
Why?
| | Enteral Nutrition | 1 | 2011 | 64 | 0.440 |
Why?
| | Abnormalities, Drug-Induced | 4 | 2016 | 9 | 0.430 |
Why?
| | Aged | 26 | 2019 | 10156 | 0.420 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2017 | 230 | 0.410 |
Why?
| | Empyema, Pleural | 1 | 2009 | 1 | 0.400 |
Why?
| | Negative-Pressure Wound Therapy | 1 | 2009 | 5 | 0.390 |
Why?
| | Neoplasm Staging | 12 | 2019 | 516 | 0.380 |
Why?
| | Intraoperative Complications | 1 | 2009 | 75 | 0.380 |
Why?
| | Echinocandins | 3 | 2012 | 7 | 0.360 |
Why?
| | Positron-Emission Tomography | 3 | 2011 | 92 | 0.360 |
Why?
| | Surgical Wound Infection | 1 | 2009 | 102 | 0.350 |
Why?
| | Male | 29 | 2019 | 17552 | 0.350 |
Why?
| | Drainage | 2 | 2009 | 55 | 0.350 |
Why?
| | Toxicity Tests | 4 | 2016 | 9 | 0.340 |
Why?
| | Female | 30 | 2019 | 18107 | 0.340 |
Why?
| | Postoperative Complications | 4 | 2016 | 1084 | 0.320 |
Why?
| | Embryonic Development | 3 | 2016 | 8 | 0.320 |
Why?
| | Retrospective Studies | 11 | 2017 | 3456 | 0.300 |
Why?
| | Embryo, Mammalian | 2 | 2016 | 37 | 0.290 |
Why?
| | Humans | 32 | 2020 | 30741 | 0.280 |
Why?
| | Solitary Pulmonary Nodule | 2 | 2015 | 14 | 0.280 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2019 | 198 | 0.270 |
Why?
| | Middle Aged | 20 | 2017 | 11256 | 0.270 |
Why?
| | Bronchoscopy | 3 | 2019 | 38 | 0.260 |
Why?
| | Pleurodesis | 1 | 2003 | 2 | 0.260 |
Why?
| | Pleural Effusion, Malignant | 1 | 2003 | 6 | 0.260 |
Why?
| | Consensus | 2 | 2020 | 96 | 0.250 |
Why?
| | Prognosis | 6 | 2017 | 1045 | 0.240 |
Why?
| | Radiosurgery | 3 | 2011 | 40 | 0.230 |
Why?
| | Antifungal Agents | 2 | 2012 | 42 | 0.230 |
Why?
| | Aged, 80 and over | 12 | 2017 | 5172 | 0.230 |
Why?
| | Treatment Outcome | 11 | 2017 | 3850 | 0.220 |
Why?
| | Survival Analysis | 5 | 2017 | 398 | 0.220 |
Why?
| | Education, Medical, Graduate | 1 | 2020 | 82 | 0.200 |
Why?
| | Surgeons | 1 | 2020 | 76 | 0.200 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2019 | 13 | 0.200 |
Why?
| | False Positive Reactions | 1 | 2019 | 40 | 0.200 |
Why?
| | Computer Simulation | 1 | 2020 | 246 | 0.200 |
Why?
| | Fetal Development | 2 | 2016 | 6 | 0.190 |
Why?
| | Cohort Studies | 4 | 2017 | 1959 | 0.190 |
Why?
| | Fetus | 2 | 2016 | 62 | 0.190 |
Why?
| | Registries | 4 | 2015 | 203 | 0.180 |
Why?
| | Bone and Bones | 2 | 2016 | 111 | 0.180 |
Why?
| | Neovascularization, Pathologic | 2 | 2015 | 70 | 0.180 |
Why?
| | Tracheomalacia | 1 | 2017 | 5 | 0.170 |
Why?
| | Tracheal Stenosis | 1 | 2017 | 8 | 0.170 |
Why?
| | Silicones | 1 | 2017 | 14 | 0.170 |
Why?
| | Airway Obstruction | 1 | 2017 | 22 | 0.170 |
Why?
| | Length of Stay | 3 | 2016 | 371 | 0.170 |
Why?
| | Mutagenicity Tests | 1 | 2016 | 1 | 0.170 |
Why?
| | Hazardous Substances | 1 | 2016 | 2 | 0.170 |
Why?
| | Multivariate Analysis | 5 | 2017 | 391 | 0.170 |
Why?
| | Teratogens | 1 | 2016 | 2 | 0.170 |
Why?
| | Clinical Competence | 2 | 2020 | 268 | 0.170 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2014 | 60 | 0.160 |
Why?
| | Pharmaceutical Preparations | 1 | 2016 | 22 | 0.160 |
Why?
| | Risk Assessment | 4 | 2017 | 804 | 0.160 |
Why?
| | Developmental Biology | 1 | 2016 | 1 | 0.160 |
Why?
| | Thoracic Wall | 1 | 2016 | 11 | 0.160 |
Why?
| | Models, Animal | 1 | 2016 | 150 | 0.160 |
Why?
| | Ribs | 1 | 2016 | 19 | 0.160 |
Why?
| | Metformin | 1 | 2016 | 21 | 0.160 |
Why?
| | Sensitivity and Specificity | 2 | 2009 | 594 | 0.160 |
Why?
| | X-Ray Microtomography | 1 | 2016 | 70 | 0.150 |
Why?
| | Stents | 1 | 2017 | 158 | 0.150 |
Why?
| | Disease Progression | 4 | 2014 | 851 | 0.150 |
Why?
| | Esophagoscopy | 1 | 2015 | 18 | 0.150 |
Why?
| | Learning Curve | 1 | 2015 | 19 | 0.150 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 76 | 0.150 |
Why?
| | Thoracoscopy | 2 | 2019 | 19 | 0.150 |
Why?
| | Insulin-Like Growth Factor II | 1 | 2014 | 10 | 0.140 |
Why?
| | Insulin-Like Growth Factor Binding Proteins | 1 | 2014 | 15 | 0.140 |
Why?
| | Rats | 5 | 2016 | 954 | 0.140 |
Why?
| | Cytokines | 2 | 2014 | 348 | 0.140 |
Why?
| | Tumor Burden | 3 | 2010 | 44 | 0.140 |
Why?
| | Intubation, Intratracheal | 2 | 2016 | 66 | 0.130 |
Why?
| | Animals | 8 | 2016 | 5221 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 2 | 2015 | 230 | 0.130 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 13 | 0.130 |
Why?
| | Multiple Pulmonary Nodules | 1 | 2013 | 9 | 0.130 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 222 | 0.130 |
Why?
| | Prosthesis Failure | 1 | 2017 | 526 | 0.130 |
Why?
| | Fundoplication | 1 | 2012 | 24 | 0.120 |
Why?
| | Research Design | 2 | 2012 | 230 | 0.120 |
Why?
| | Gastroesophageal Reflux | 1 | 2012 | 33 | 0.120 |
Why?
| | Immunoassay | 1 | 2012 | 44 | 0.120 |
Why?
| | Nitriles | 1 | 2012 | 17 | 0.120 |
Why?
| | Pyrimidines | 1 | 2012 | 32 | 0.120 |
Why?
| | Diagnosis, Differential | 2 | 2015 | 469 | 0.120 |
Why?
| | Predictive Value of Tests | 4 | 2016 | 631 | 0.120 |
Why?
| | Triazoles | 1 | 2012 | 35 | 0.120 |
Why?
| | Gastric Fistula | 1 | 2011 | 4 | 0.120 |
Why?
| | Fistula | 1 | 2011 | 7 | 0.120 |
Why?
| | Disease-Free Survival | 3 | 2017 | 247 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2016 | 527 | 0.110 |
Why?
| | Nutrition Assessment | 1 | 2011 | 53 | 0.110 |
Why?
| | Hospitals, Community | 1 | 2011 | 22 | 0.110 |
Why?
| | Community-Institutional Relations | 1 | 2011 | 15 | 0.110 |
Why?
| | Pyrazoles | 1 | 2012 | 55 | 0.110 |
Why?
| | Radiography, Interventional | 1 | 2011 | 30 | 0.110 |
Why?
| | Medical Oncology | 1 | 2011 | 39 | 0.110 |
Why?
| | Anticarcinogenic Agents | 1 | 2010 | 21 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 5 | 2015 | 876 | 0.110 |
Why?
| | Receptor, IGF Type 1 | 1 | 2010 | 21 | 0.110 |
Why?
| | Minority Groups | 1 | 2011 | 71 | 0.110 |
Why?
| | Behavior, Animal | 1 | 2011 | 109 | 0.110 |
Why?
| | Bronchi | 1 | 2010 | 19 | 0.110 |
Why?
| | Prospective Studies | 5 | 2015 | 1891 | 0.110 |
Why?
| | Algorithms | 3 | 2014 | 421 | 0.110 |
Why?
| | Adult | 8 | 2017 | 9760 | 0.110 |
Why?
| | Trachea | 1 | 2010 | 23 | 0.100 |
Why?
| | Heart Diseases | 1 | 2011 | 102 | 0.100 |
Why?
| | Thoracic Surgical Procedures | 1 | 2009 | 12 | 0.100 |
Why?
| | Risk Factors | 5 | 2015 | 2611 | 0.100 |
Why?
| | Probability | 1 | 2009 | 107 | 0.100 |
Why?
| | Age Factors | 2 | 2009 | 941 | 0.100 |
Why?
| | Patient Selection | 1 | 2011 | 259 | 0.100 |
Why?
| | Thoracic Surgery | 1 | 2009 | 33 | 0.100 |
Why?
| | Statistics, Nonparametric | 1 | 2009 | 162 | 0.100 |
Why?
| | Area Under Curve | 3 | 2014 | 78 | 0.100 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 386 | 0.100 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 311 | 0.090 |
Why?
| | Staphylococcus aureus | 1 | 2009 | 83 | 0.090 |
Why?
| | Body Mass Index | 1 | 2011 | 438 | 0.090 |
Why?
| | Survival Rate | 2 | 2010 | 478 | 0.090 |
Why?
| | Recurrence | 2 | 2014 | 390 | 0.090 |
Why?
| | Neoplasms | 1 | 2011 | 275 | 0.090 |
Why?
| | Rats, Inbred F344 | 3 | 2012 | 51 | 0.090 |
Why?
| | Laparoscopy | 1 | 2009 | 188 | 0.090 |
Why?
| | United States | 4 | 2015 | 2467 | 0.080 |
Why?
| | Staphylococcal Infections | 1 | 2009 | 172 | 0.080 |
Why?
| | Neoplasm Invasiveness | 2 | 2017 | 109 | 0.080 |
Why?
| | Lung | 2 | 2005 | 169 | 0.080 |
Why?
| | Rabbits | 2 | 2016 | 327 | 0.080 |
Why?
| | Pregnancy | 3 | 2012 | 452 | 0.080 |
Why?
| | Pneumonia | 2 | 2019 | 75 | 0.080 |
Why?
| | Protein-Lysine 6-Oxidase | 1 | 2005 | 1 | 0.080 |
Why?
| | Carcinoma, Bronchogenic | 1 | 2005 | 14 | 0.070 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2009 | 296 | 0.070 |
Why?
| | Time Factors | 3 | 2015 | 1911 | 0.070 |
Why?
| | Logistic Models | 2 | 2015 | 479 | 0.070 |
Why?
| | ROC Curve | 2 | 2014 | 155 | 0.070 |
Why?
| | Catheters, Indwelling | 1 | 2003 | 29 | 0.060 |
Why?
| | Follow-Up Studies | 3 | 2014 | 2046 | 0.060 |
Why?
| | Proton Pump Inhibitors | 2 | 2012 | 15 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2016 | 875 | 0.060 |
Why?
| | Incidence | 2 | 2015 | 827 | 0.060 |
Why?
| | Brain | 1 | 2011 | 1574 | 0.060 |
Why?
| | Mediastinoscopy | 1 | 2019 | 5 | 0.050 |
Why?
| | Sex Factors | 2 | 2012 | 535 | 0.050 |
Why?
| | Reoperation | 2 | 2015 | 918 | 0.050 |
Why?
| | Early Detection of Cancer | 1 | 2019 | 91 | 0.040 |
Why?
| | Radiography | 2 | 2013 | 714 | 0.040 |
Why?
| | Dilatation | 1 | 2017 | 13 | 0.040 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2016 | 10 | 0.040 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 36 | 0.040 |
Why?
| | Pneumonia, Bacterial | 1 | 2016 | 15 | 0.040 |
Why?
| | Young Adult | 2 | 2014 | 2249 | 0.040 |
Why?
| | Tracheostomy | 1 | 2016 | 27 | 0.040 |
Why?
| | Protective Factors | 1 | 2015 | 18 | 0.040 |
Why?
| | Observer Variation | 1 | 2016 | 146 | 0.040 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2015 | 21 | 0.040 |
Why?
| | Least-Squares Analysis | 1 | 2015 | 9 | 0.040 |
Why?
| | Hospitals, Low-Volume | 1 | 2015 | 7 | 0.040 |
Why?
| | Hospitals, High-Volume | 1 | 2015 | 10 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2016 | 78 | 0.040 |
Why?
| | Cause of Death | 1 | 2015 | 74 | 0.040 |
Why?
| | Databases, Factual | 1 | 2017 | 372 | 0.040 |
Why?
| | Remission Induction | 1 | 2015 | 127 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2015 | 181 | 0.040 |
Why?
| | Minnesota | 1 | 2014 | 12 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2016 | 385 | 0.040 |
Why?
| | Diabetes Mellitus | 1 | 2016 | 140 | 0.040 |
Why?
| | Linear Models | 1 | 2015 | 277 | 0.040 |
Why?
| | Odds Ratio | 1 | 2015 | 328 | 0.030 |
Why?
| | Illinois | 1 | 2014 | 268 | 0.030 |
Why?
| | Chemokine CCL3 | 1 | 2013 | 12 | 0.030 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2013 | 15 | 0.030 |
Why?
| | Granuloma | 1 | 2013 | 16 | 0.030 |
Why?
| | Chemokine CXCL12 | 1 | 2013 | 9 | 0.030 |
Why?
| | Interleukin-10 | 1 | 2013 | 42 | 0.030 |
Why?
| | Respiratory Tract Infections | 1 | 2013 | 53 | 0.030 |
Why?
| | Maternal Exposure | 1 | 2012 | 2 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2013 | 120 | 0.030 |
Why?
| | Decision Support Techniques | 1 | 2012 | 54 | 0.030 |
Why?
| | Voriconazole | 1 | 2012 | 7 | 0.030 |
Why?
| | Injections, Subcutaneous | 1 | 2012 | 45 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2012 | 111 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2012 | 50 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2012 | 39 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2012 | 77 | 0.030 |
Why?
| | Cesarean Section | 1 | 2012 | 33 | 0.030 |
Why?
| | Drug Combinations | 1 | 2012 | 88 | 0.030 |
Why?
| | Hematemesis | 1 | 2011 | 2 | 0.030 |
Why?
| | Stomach Ulcer | 1 | 2011 | 5 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 228 | 0.030 |
Why?
| | Esophageal Perforation | 1 | 2011 | 10 | 0.030 |
Why?
| | Administration, Oral | 1 | 2012 | 165 | 0.030 |
Why?
| | Candidiasis | 1 | 2011 | 18 | 0.030 |
Why?
| | Osteogenesis | 1 | 2012 | 94 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2011 | 76 | 0.030 |
Why?
| | Body Weight | 1 | 2012 | 165 | 0.030 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2011 | 29 | 0.030 |
Why?
| | Michigan | 1 | 2011 | 20 | 0.030 |
Why?
| | Sex Distribution | 1 | 2011 | 91 | 0.030 |
Why?
| | Feeding Behavior | 1 | 2012 | 123 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2011 | 64 | 0.030 |
Why?
| | Organogenesis | 1 | 2010 | 2 | 0.030 |
Why?
| | Maternal-Fetal Exchange | 1 | 2010 | 11 | 0.030 |
Why?
| | Macaca fascicularis | 1 | 2010 | 28 | 0.030 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2010 | 22 | 0.030 |
Why?
| | Program Evaluation | 1 | 2011 | 152 | 0.030 |
Why?
| | Contrast Media | 1 | 2011 | 147 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2011 | 79 | 0.030 |
Why?
| | Rupture | 1 | 2010 | 115 | 0.030 |
Why?
| | Hospitalization | 1 | 2012 | 344 | 0.020 |
Why?
| | Comorbidity | 1 | 2011 | 562 | 0.020 |
Why?
| | Motor Activity | 1 | 2011 | 395 | 0.020 |
Why?
| | Radiotherapy Dosage | 1 | 2007 | 147 | 0.020 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2007 | 74 | 0.020 |
Why?
| | Mice | 1 | 2012 | 1843 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 206 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2005 | 361 | 0.020 |
Why?
| | Cognition | 1 | 2011 | 1141 | 0.020 |
Why?
| | Aging | 1 | 2012 | 1551 | 0.010 |
Why?
|
|
Chmielewski's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|